Intended population
Adults with clinically diagnosed atrial fibrillation undergoing assessment of stroke and systemic thromboembolism risk.
Guideline-supported
CHA₂DS₂-VA
Estimates thromboembolic risk in patients with atrial fibrillation using clinical risk factors without including sex as a scoring component.
Score range
0–8 points
Patient variables
Enter the clinical information
years
Important limitations
The score does not capture every modifier of thromboembolic or bleeding risk and must not be used as the sole basis for clinical decisions.
Scientific status
Guideline-supported clinical risk classification. Formula and interpretation require documented scientific review before public release.
Reference
Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Løchen ML, Lumbers RT, Maesen B, Mølgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. Erratum in: Eur Heart J. 2025 Nov 3;46(41):4349. doi: 10.1093/eurheartj/ehaf306. PMID: 39210723.